Camurus AB
STO:CAMX
Intrinsic Value
Camurus AB operates as a research based pharmaceutical company. [ Read More ]
The intrinsic value of one CAMX stock under the Base Case scenario is 841.51 SEK. Compared to the current market price of 482.8 SEK, Camurus AB is Undervalued by 43%.
Valuation Backtest
Camurus AB
Run backtest to discover the historical profit from buying and selling CAMX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Camurus AB
Current Assets | 1.6B |
Cash & Short-Term Investments | 1.2B |
Receivables | 300.8m |
Other Current Assets | 133.5m |
Non-Current Assets | 283.8m |
PP&E | 39.7m |
Intangibles | 22.7m |
Other Non-Current Assets | 221.3m |
Current Liabilities | 368.6m |
Accounts Payable | 99.3m |
Accrued Liabilities | 213.7m |
Other Current Liabilities | 55.6m |
Non-Current Liabilities | 46.2m |
Long-Term Debt | 13.6m |
Other Non-Current Liabilities | 32.6m |
Earnings Waterfall
Camurus AB
Revenue
|
1.7B
SEK
|
Cost of Revenue
|
-122.3m
SEK
|
Gross Profit
|
1.6B
SEK
|
Operating Expenses
|
-1.1B
SEK
|
Operating Income
|
533.4m
SEK
|
Other Expenses
|
-102m
SEK
|
Net Income
|
431.4m
SEK
|
Free Cash Flow Analysis
Camurus AB
CAMX Profitability Score
Profitability Due Diligence
Camurus AB's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
Score
Camurus AB's profitability score is 59/100. The higher the profitability score, the more profitable the company is.
CAMX Solvency Score
Solvency Due Diligence
Camurus AB's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Score
Camurus AB's solvency score is 99/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CAMX Price Targets Summary
Camurus AB
According to Wall Street analysts, the average 1-year price target for CAMX is 570.69 SEK with a low forecast of 449.45 SEK and a high forecast of 724.5 SEK.
Shareholder Return
CAMX Price
Camurus AB
Average Annual Return | 48.02% |
Standard Deviation of Annual Returns | 60.17% |
Max Drawdown | -44% |
Market Capitalization | 26.9B SEK |
Shares Outstanding | 57 623 600 |
Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Camurus AB operates as a research based pharmaceutical company. The company is headquartered in Lund, Skane and currently employs 148 full-time employees. The company went IPO on 2015-12-03. The firm has a diversified research portfolio, which includes five products in clinical trials, and a number of additional product candidates in the pre-clinical phase. The Company’s product pipeline represents a mix of in-house and partnered projects in different development phases. Camurus AB is the parent company of the Group, which comprises four legal entities, namely Camurus Inc, Cubosome Inc, Camurus Development AB and Bioimplant Scandinavia AB.
Contact
IPO
Employees
Officers
The intrinsic value of one CAMX stock under the Base Case scenario is 841.51 SEK.
Compared to the current market price of 482.8 SEK, Camurus AB is Undervalued by 43%.